Acticor Biotech Is A Clinical Stage Biopharmaceutical Company That Focuses On Acute Thrombotic Diseasesparticularly In The Area Of Ischemic Stroke Treatmentfounded In 2013 As A Spin Off From Insermthe Company Is Dedicated To Developing Innovative Therapies For Cardiovascular Emergencies The Key Product In Acticor S Pipeline Is Glenzocimaba Monoclonal Antibody Designed To Inhibit Pathological Thrombus Formation While Preserving Hemostasisthis First In Class Therapeutic Targets Platelet Glycoprotein Vigpviand Aims To Reduce Thrombotic Complications Without Increasing Bleeding Risksacticor Positions Itself As One Of The Few Publicly Listed Companies Globally Specializing In Ischemic Stroke Therapeuticshighlighting Its Unique Value In The Market
